LSE · GDR.L
Genedrive Plc
£0.01-£0.00 (-0.92%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.68% below the high.
Loading market information…
LSE · MHC.L · GBp
Stock price, earnings
Quote as of Nov 10, 2025, 02:53 PM UTC. Cached market data; not a live quote.
One-year closing-price history · GBp. Historical prices are not a forecast.
MyHealthChecked PLC’s quoted price sits in the lower half of its reported 52-week range, 58.33% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow MyHealthChecked PLC’s reporting calendar.
THE COMPANY BEHIND THE TICKER
MyHealthChecked PLC specializes in the creation and distribution of at-home health and wellbeing diagnostic solutions across the United Kingdom. Its product line encompasses the production and supply of the MyLotus testing strip. Additionally, the company offers COVID-19 sample collection kits under its MyHealthChecked brand, alongside a variety of other DNA and RNA self-testing options. Established in 2008, the firm was initially known as Concepta PLC before rebranding to MyHealthChecked PLC in December 2020, with its headquarters located in Cardiff, UK.
Latest available per-share figures in GBP. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 08:27 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
£0.01-£0.00 (-0.92%)
Genedrive Plc’s quoted price sits in the lower half of its reported 52-week range, 37.68% below the high.
£0.07£0.00 (0.0%)
Tissue Regenix Group plc’s quoted price sits in the lower half of its reported 52-week range, 89.02% below the high.
£0.01+£0.00 (+4.29%)
Proteome Sciences plc’s quoted price sits in the lower half of its reported 52-week range, 66.82% below the high.
£0.00£0.00 (0.0%)
N4 Pharma Plc’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
£0.00-£0.00 (-2.86%)
Theracryf Plc’s quoted price sits in the lower half of its reported 52-week range, 36.57% below the high.
£0.09£0.00 (0.0%)
CRISM Therapeutics Corporation’s quoted price sits in the lower half of its reported 52-week range, 52.7% below the high.
£0.00-£0.00 (-12.5%)
Surgical Innovations Group plc’s quoted price sits in the lower half of its reported 52-week range, 41.67% below the high.
£0.06-£0.00 (-1.79%)
Feedback plc’s quoted price sits in the lower half of its reported 52-week range, 63.33% below the high.
